Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06347068
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2024-03-22
Brief Title:
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CARB7-H3 T Cells
Sponsor:
UNC Lineberger Comprehensive Cancer Center
Organization:
UNC Lineberger Comprehensive Cancer Center
Study Overview
Official Title:
Study of Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors and Containing the Inducible Caspase 9 Safety Switch in Subjects With Triple Negative Breast Cancer
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase 1 single-center open-label study explores the safety of escalating doses of chimeric antigen receptor T cells CAR-T cells in subjects with relapsedrefractory triple-negative breast cancer TNBC
Detailed Description:
T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen iC9-CARB7-H3 T cells treatment is experimental and has not been approved by the Food and Drug Administration The safety of iC9-CARB7-H3 T cells will be investigated using a modified 33 design The data from the dose escalation will be used to determine a recommended phase 2 dose RP2D which will be decided based on the maximum tolerated dose MTD and additional factors such as the ability to manufacture sufficient cells for infusion
Subjects with TNBC who meet procurement eligibility criteria will have cells collected to manufacture iC9-CARB7-H3 T cells Eligible subjects will receive lymphodepletion with cyclophosphamide and fludarabine
Subjects with TNBC who meet procurement eligibility criteria will have cells collected to manufacture iC9-CARB7-H3 T cells Eligible subjects will receive lymphodepletion with cyclophosphamide and fludarabine
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None